mRNA Translation Modulators Pipeline

Our high scale screening platform identifies compounds that modulate mRNA biology. Our mRNA AI image analysis then rapidly elucidates their mechanism of action.

With this unique approach we were able to develop a broad pipeline of small molecule mRNA drugs, advancing 18 discovery programs across therapeutic areas at unparalleled speed and success rate.

Anima wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc translation inhibitors and mutation agnostic mKras translation inhibitors), and Neuroscience (Tau - Alzheimer’s disease and Pain - Nav1.7 translation inhibitors) with additional programs in Repeat Associated Diseases. In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our large scale collaborations with Lilly and Takeda Pharmaceuticals.